Patent · US Active

Neuregulin allosteric anti-HER3 antibody

US10196455B2 · kind B2 · utility

0Cited by

0References

14Claims

0Family size

Assignees

INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
Universite De Montpellier · FR
INSTITUT REGIONAL DU CANCER DE MONTPELLIER (ICM) · FR

Inventors

Thierry Chardes · Montpellier, FR
Nadege Gaborit · Rehovot, IL
Christel Larbouret · Castelnau-le-Lez, FR
Andre Pelegrin · Montpellier, FR

Key dates

Filing date	Nov 7, 2013
Grant date	Feb 5, 2019
Priority date	—
Expiry date	Nov 7, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to neuregulin (NRG)-non competitive allosteric anti-human-HER3 antibodies and uses thereof in diagnostic and therapeutic methods.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.